The F.D.A. Delays Action on Covid Shots for Young Children.

February 14, 2022

(New York Times) – In a striking reversal, federal regulators said on Friday that they would wait for data on whether three doses of Pfizer-BioNTech’s coronavirus vaccine are effective in children younger than 5 before deciding whether to authorize a vaccine for the age group. The Food and Drug Administration will postpone a meeting of outside experts that was scheduled for Tuesday; the experts were to weigh the evidence and make a recommendation on whether to authorize two doses of the vaccine in young children, as Pfizer had requested. (Read More)